SCHEMBL28429820

SCHEMBL28429820

CN1CCC(CCOc2[c]cc(-c3ccccc3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HRH3 Q9Y5N1 5/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
CXCR1 P25024 1/20 0.39
ACHE P22303 3/20 0.39
BCHE P06276 2/20 0.38
AVPR2 P30518 1/20 0.38
AVPR1A P37288 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
TEAD1 P28347 1/20 0.37
TEAD3 Q99594 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28432538 0.81 HRH3 (0.39) NPC1RAB9AHRH3SCN1ASCN2A
SCHEMBL28424137 0.81 RAB9A (0.56) NPC1RAB9AHRH3AVPR2AVPR1A
SCHEMBL28425997 0.80 RAB9A (0.65) NPC1RAB9AHRH3CXCR1AVPR2
SCHEMBL3133790 0.77 RAB9A (0.45) NPC1RAB9AHRH3CXCR1TEAD1
SCHEMBL21462366 0.74 KDM4E (0.42) HRH3ACHEBCHEDRD2DRD4
SCHEMBL11413217 0.72 LTA4H (0.43) RAB9A
SCHEMBL28893962 0.72 NPC1 (0.65) NPC1RAB9AAVPR1ADRD4
SCHEMBL3142209 0.71 NPC1 (0.44) NPC1RAB9AHRH3CXCR1TEAD1
SCHEMBL28432592 0.71 RAB9A (0.56) NPC1RAB9AHRH3SCN1ASCN2A
SCHEMBL8265989 0.70 RAB9A (0.46) NPC1RAB9AHRH3CXCR1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105611-A Pharmaceutical combination comprising a Histone Deacetylase (HDAC) inhibitor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer 4SC股份公司 2020-12-18 CN disclosed
CN-112055589-A Combination comprising an HDAC inhibitor, a LAG-3 inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor for the treatment of cancer 4SC股份公司 2020-12-08 CN disclosed
CN-112004535-A Combination comprising an HDAC inhibitor and a CD137 agonist for cancer therapy 4SC股份公司 2020-11-27 CN disclosed
CN-111432884-A Combination of HDAC inhibitors with immune checkpoint modulators for cancer therapy 4SC股份公司 2020-07-17 CN disclosed